StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-22 | $16.39 | $16.65 | +1.59% | 7.4M |
| 05-26 | $16.66 | $16.26 | -2.40% | 11.4M |
| 05-27 | $16.43 | $16.29 | -0.85% | 6.8M |
| 05-28 | $16.18 | $16.11 | -0.40% | 8.4M |
| 05-29 | $16.06 | $16.26 | +1.25% | 16.9M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
6-factor scoring with sector-relative rank. Updated daily.
Each row shows where VTRS sits in our scored universe today on a single observational measurement. P85 means VTRS ranks above 85% of peers on that factor right now. Percentile rankings are descriptive — they are not buy/sell signals or quality judgments. Universe refreshed every 60 seconds.
Today's volume vs prior session average.
Absolute daily price move vs peers.
24h article count relative to the universe.
AI-classified polarity of recent news.
Today's dollar turnover (volume × VWAP).
Signed daily return vs the rest of the universe.
Stonvex publishes percentile measurements as observational data only. Nothing here constitutes a recommendation, prediction, or advice about whether to buy, sell, or hold any security. Stonvex is not a registered investment advisor.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $3.51B | $14.25B | $10.56B | $6.81B |
Operating Income | $-79.70M | $-2.66B | $-2.47B | $-2.65B |
Net Income | $176.40M | $-3.51B | $-3.17B | $-3.05B |
EPS (Diluted) | $0.15 | $-3.00 | $-2.70 | $-2.58 |
Total Assets | $36.83B | $37.19B | $37.92B | $38.41B |
Total Liabilities | $22.18B | $22.48B | $22.70B | $22.84B |
Cash & Equivalents | $1.80B | $1.32B | $975.30M | $566.40M |
Free Cash Flow OCF − CapEx | $348.40M | $1.94B | $1.32B | $659.70M |
Shares Outstanding | 1.18B | Not available | 1.18B | 1.18B |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.
No sell-side coverage available for VTRS yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
What drives VTRS's price movement
Big money drives this stock. Watch dark pool activity, block trades, and 13F filings.
Heavy institutional participation drives this stock
Outperforming sector peers — leadership position
Moderate news sensitivity
Moderate sentiment influence
Mixed retail/institutional activity
Not momentum-driven — mean-reverts quickly
DNA analysis is based on current factor scoring. Not investment advice.